chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 30Nov2022 as dose 5 (booster), single (Lot number: GJ6796) at the age of 68 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 01Mar2021 as dose 1, single (Lot number: EN6203), in left arm, on 22Mar2021 as dose 2, single (Lot number: ER2613), in left arm, on 05Oct2021 as dose 3 (booster), single (Lot number: FF2587), in left arm and on 18Jul2022 as dose 4 (booster), single (Lot number: FM7553), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Seizure" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "prostate cancer" (unspecified if ongoing); "Known allergies: Seasonal" (unspecified if ongoing). Concomitant medication(s) included: OXCARBAZEPINE; NEBIVOLOL; CETIRIZINE; ACETAMINOPHEN; DEXTROMETHORPHAN; GUAIFENESIN; PHENYLEPHRINE; TRIPROLIDINE. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2022) Positive, notes: Result of antigen test was positive; (Dec2022) Negative, notes: Antigen test three days prior was negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid (Treatment start date: 08Dec2022, Treatment stop date: 12Dec2022).
Severe runny nose 2-3 days after booster. Runny nose for 3 days. Zyrtec did not stop the nose from running.   Sore arm but expected as with the first two shots.
Sore swollen neck on left side, same as injection side.  Nausea, headache, and joint pain the next day.  Never had the swollen neck before with other 2 injections.
shingles to right top of head, ulcers in mouth, teeth pain, and rash to right side of face. all symptoms are right sided
Patient was given BOOSTRIX (Tdap) in LD around 11:30 10-16-12. She states she ran errands & then went home to take a nap. When she woke up around 1600 on 10-16-12, she noticed swelling bilaterally in all 4 extremities & she felt like she had something in her throat. She called her primary Dr. office & was Rx liquid BENADRYL. Spoke with patient this AM & she states only swelling noted to (L) ankle.
No symptoms of immediate adverse reaction. But there were delayed reactions around two months after the Covid vaccine. (And the following symptoms I am about to report in THIS present form also happened with the Pfizer I received 5/7/21which I did not report to VAERS).  This is why I am reporting the 5/12/22 event because they were the same reactions I experienced at approximately the same span of time  of about two months after the vaccine was administered. The reactions began with constricted breathing at night that became exacerbated with no evidence of any infection or illness. I had to go on medications (220 twice daily fluticasone) preceded with a prednisone burst to achieve stability. I had not used any breathing support medications prior to these Covid vaccines except in 2015 when I had a diagnosed pneumonia which was successfully treated with several months of fluticasone until I was well. Since then I have not needed any medications for breathing until after the 2021 and 2022 vaccines. I have no evidence of pneumonia or any other illness. The breathing events show up a couple of months after the vaccine.  When it happened in 2021, I needed a prednisone burst to get out of the crisis and follow up with large doses of fluticasone 220 twice a day until things stabilized. I maintained the low dose for the rest of the year so as not to be caught off guard due to the need to have more Covid vaccines. I was at the low dose during the time I received the Covid vaccine on 5/12/22 of this year. However, after two months I again had a breathing crisis, despite being on the Flovent daily. So it appears to me that I seem to react with increased breathing events around two months after receiving the Covid vaccine, when I have been previously stable. The only report I made with VAERS concerning the Covid vaccine in the past was in the year of 2021, with the first vaccine. The symptoms then included an unusual skin rash of patches on my upper body. It was self limiting but very unusual since I had never experienced this in my life and had no known contact with any allergens but happened a few weeks after that first Covid dose. Seems like every time I have a Covid vaccine I have a reaction. I had a skin reaction in February after receiving the Covid vaccine on 12/28/21. It seems unusual to me that I have had numerous reactions that have no apparent explanation other than there is consistency with the timing of the reactions at approximately two months. It is an unusual coincidence and worth reporting. I'm concerned that the need for the body to ramp up the immune system long enough to last until the next vaccine possibly results in these adverse events that seem to have no other explanation. I have not experienced any of these symptoms at any other time and have no known medical condition that would precipitate them. Additionally, I am otherwise a very healthy person and work very hard to maintain an excellent diet and routine exercise. I don't smoke, maintain positive healthy relationships and have a strong spiritual community. I am very self aware and these events are a mystery due to my intense management of my good health.
Started to have twitching fits / symptoms resembling epilepsy a few months after the vaccine was administered
Directly after the vaccine  experienced sharp pain up and down left arm. Severe body aches and sweats.  Was in sever pain and suffering , nausea. Was unable to finish work day; Directly after the vaccine  experienced sharp pain up and down left arm. Severe body aches and sweats.  Was in sever pain and suffering , nausea. Was unable to finish work day; Directly after the vaccine  experienced sharp pain up and down left arm. Severe body aches and sweats.  Was in sever pain and suffering , nausea. Was unable to finish work day; Directly after the vaccine  experienced sharp pain up and down left arm. Severe body aches and sweats.  Was in sever pain and suffering , nausea. Was unable to finish work day; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 25-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Apr2022 at 09:00 as dose 1, single (Lot number: FP54454) at the age of 25 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: NAUSEA (disability, life threatening), PAIN IN EXTREMITY (disability, life threatening), PAIN (disability, life threatening), HYPERHIDROSIS (disability, life threatening) all with onset 22Apr2022 at 11:00, outcome "not recovered" and all described as "Directly after the vaccine  experienced sharp pain up and down left arm. Severe body aches and sweats.  Was in sever pain and suffering , nausea. Was unable to finish work day". Therapeutic measures were taken as a result of nausea, pain in extremity, pain, hyperhidrosis.  Clinical Information: Directly after the vaccine patient experienced sharp pain up and down patient left arm. Severe body aches and sweats.  Was in sever pain and suffering, nausea. Was unable to finish her workday. No prolonged Hospitalization. No known allergies. Prior to vaccination, Patient was did not diagnosed with COVID-19. Since the vaccination, Patient has not been tested for COVID-19. Device Date: 23Apr2022. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Did not received any other medications received within 2 weeks of vaccination.
Reactions from the 2nd vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE EVENT (Reactions from the 2nd vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ADVERSE EVENT (Reactions from the 2nd vaccine). At the time of the report, ADVERSE EVENT (Reactions from the 2nd vaccine) outcome was unknown.            No concomitant medications were reported. No treatment information was provided.
discovered a tumor in left side of the brain; This spontaneous case was reported by a consumer and describes the occurrence of BRAIN NEOPLASM (discovered a tumor in left side of the brain) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BRAIN NEOPLASM (discovered a tumor in left side of the brain) (seriousness criteria hospitalization and medically significant). At the time of the report, BRAIN NEOPLASM (discovered a tumor in left side of the brain) outcome was unknown.            No concomitant medication details were provided. No treatment medication details were provided.  Reporter advised patient was now in ICU and that patient that he was probably in his 50s.  This case concerns a male patient with no relevant medical history reported, who experienced the unexpected event of brain neoplasm. The events occurred after the second dose of Spikevax. The rechallenge was not applicable. The benefit-risk relationship of Spikevax is not affected by this report.; Sender's Comments: This case concerns a male patient with no relevant medical history reported, who experienced the unexpected event of brain neoplasm. The events occurred after the second dose of Spikevax. The rechallenge was not applicable. The benefit-risk relationship of Spikevax is not affected by this report.
Birth weight 8 pounds 11ounces full term (9days late)  After I had my child, I anticipated having crazy cycles due to birth as well as breast feeding. Sometimes I would have a period every other month and sometimes I would go two months without a cycle. The cycle was very unpredictable. Before getting the vaccine, my cycle was within 2-3 days to the date. Now I just don't know when or if I am going to have a cycle at all.  I did get the booster and after that I did have regular cycles June, July, and August was early and no cycle in September. The doctors feel that my cycles could've been affected yet again.
Patient experienced a near syncopal episode within 5 minutes of receiving the vaccine. He was seated in table in the back of the room of the Observation area. He had been put there as during his first COVID vaccine on 4/21/2021 he fainted and went to the ER. He has been suffering from mild concussion symptoms since 4/21 such as headaches and fatigue. His vitals at 9:15 were BP 138/88, HR 102, O2 Sat 97%. ARNP assisted pt. with an ice pack to his forehead and assessed mental status. He was alert and oriented x 3, no neck pain, pale, no disturbed vision, able to move hands and legs. He had eaten ~8 oz of yogurt and a peach at 8:45 just prior to the vaccine at 9:10. While with us he drank 6 oz of apple juice followed by vitals of 125/76 and pulse of 74 along with O2 Sat of 99% Student is a graduated senior at the University  where he received both vaccines. He is originally from out of town and will return there in 6 days. He remained with us for 40 minutes. He was released to walk home with a friend (~ 3 blocks) and rest for the remainder of the day. Spoke with pt. 3 hours later and no s/s, no negative reaction-feels well
pt recv vax 10MAR97 lt arm sx appeared on 11MAR97 8Am lt arm muscle hard, swollen, inc redness & painful upon movement & touch;
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 11-OCT-2017, the patient was vaccinated with an improperly stored dose of PROQUAD lot # M048201 with expiry date 05-JUN-2018 or lot # N008826 with expiry date 12-SEP-2018 (dose, vaccination site and route of administration were not reported) for prophylaxis. No adverse effects were reported. Administered dose of vaccine underwent a temperature excursion from 6 degrees Fahrenheit to 14 degrees Fahrenheit for 30 minutes. Digital data logger was involved. There were no previous temperature excursions reported. This is one of three reports received from the same reporter.; Sender's Comments: US-009507513-1711USA009218: US-009507513-1711USA009219:
I have had Night sweats every night since the second vaccine.  no other symptoms during the day.  just at night.  Had no issues prior to vaccine.  Today would be 2 weeks post.  Woke up 3 times drenched last nights and had to sleep in different locations in the home becuase the bed was wet with sweat.
minor fever; Inappropriate Age at Vaccine Administration; overdose; This case was reported by a other health professional via call center representative and described the occurrence of fever in a 19-month-old female patient who received HAV (Havrix adult) (batch number 37RY4, expiry date 6th March 2021) for prophylaxis.  On 22nd March 2019, the patient received Havrix adult. On 22nd March 2019, unknown after receiving Havrix adult, the patient experienced adult product administered to child and overdose. On an unknown date, the outcome of the adult product administered to child and overdose were unknown.  Additional details were provided as follows: The medical assistant gave adult dose of Havrix to an infant patient, which led to inappropriate age at vaccine administration and overdose. The vaccine coordinator reported that he did not have the information and that the medical assistant would need to provide it. No additional details were provided.   Follow up information received from other health professional on 30th April 2019: The patient's demographic details were updated. The patient received the 1st dose of Havrix adult intramuscularly and less than a year after experienced minor fever. The reporter grabbed adult dose Vs. pediatric dose, container were labelled correctly in fridge. The medical assistant just took wrong vaccine. The patient's parent were contacted.  The reporter reported that the patient was doing fine with a minor fever. It was unknown if the reporter considered the fever to be related to Havrix adult. The VAERS details were updated. This was a medication error with harm.
hard knot & red around inj site-turned to big red ring that looked like a rash;
This spontaneous report as received from a nurse practitioner refers to a 16 year old female patient. The patient had no relevant medical history or drug allergy On 30-JAN-2013 the patient was vaccinated with first dose of GARDASIL (lot # 672834/0131AE, expiry date 26-OCT-2014) intramuscularly. No concomitant therapy reported. On 01-FEB-2013, 2 days after the vaccination, the patient developed red itchy rash over her whole body (head to toe). The patient contacted office for medical attention. She received over the counter antihistamines (manufacturer unspecified) as treatment. No lab tests were performed. On 02-FEB-2013, about 24 hours after starting, the patient recovered from the event. The reporter did not assess causality of the event. Additional information has been requested.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. Relevant medical history and concomitant medication were not provided. On 14-JUN-2013 the patient was vaccinated with RECOMBIVAX HB. Lot number 1520Z. Dose, route and frequency were not provided. On 14-JUN-2013, the patient was vaccinated with RECOMBIVAX which expired on 04-MAY-2013. The patient did not experience an adverse event. The outcome of vaccinated on 14-JUN-2013 with RECOMBIVAX which expired on 04-MAY-2013 and no adverse event was unknown. The reporter considered vaccinated on 14-JUN-2013 with RECOMBIVAX which expired on 04-MAY-2013 and no adverse event to be not related to RECOMBIVAX HB. Additional information has been requested.
Severe muscle aches and joint pain.  Fever of 101-101.7 (with tylenol). Sever symptoms lasted about 32 hours and prevented normal daily functioning and activities.
the soreness in the arm was less the second time than the first; This is a spontaneous report received from a  sponsored program. A con-tactable consumer reported that a patient of unspecified age and gender received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunization.The patients medical  history was unknown. The patients concomitant medication included estrogens conjugated (PREMARIN) taken for an unspecified indication, start and stop date were not reported.The patient stated that she had problems with her eyes. she stated that after she had  her second COVID vaccine shot, not only did it not have any after effects, but the soreness in the arm was less the second time than the first. The outcome of the events was unknown.  Information on lot number/batch number was requested.
vaccine admin. at 3:55, at 4:25 patient returned with hives over various areas of the body, at 4:35 administered 50mg diphenhydramine liq per Dr.'s order, rash reduced by 4:55 PM
hearing loss, left ear, noticed 1 day after second vaccine (4/28/2021-present).  Treated with 60 mg/day oral prednisone for 14 days, plus 5-day taper (50, 40, 30, 20, 10 mg).  As of day 14, no noticeable improvement.  Audiogram performed 5/3/2021.  Second audiogram scheduled for 5/20/2021.  Fever, fatigue, malaise (4/28-5/5)
Information has been received from a licensed practical nurse (L.P.N.) concerning a 7-year-old white male who on 22-DEC-1999 was vaccinated subcutaneously in the right leg with a first dose of Varivax (lot# 631776/1351J). Subsequently, the patient developed what the physician diagnosed as chickenpox. No outcome was reported. Additional information has been requested.
given Pfizer due to unknown history of two Moderna Vaccines - card was not available - but a xerox was presented after the shot.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose12/24/21 2nd dose01/14/21 Diagnosed covid positive:09/04/21 Symptom onset:08/26/21 Exposure:home Symptoms:cough, fatigue,muscle aches,sore throat,runny nose.
FELT LIKE TRASH FOR 6 DAYS; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on APR-2021 for prophylactic vaccination. The batch number was not reported. As per procedure no follow-up will be requested for this case. No concomitant medications were reported.  On 2021, the subject experienced felt like trash for 6 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from felt like trash for 6 days on 2021. This report was non-serious.
Allergic reaction to the bovine content on an unspecified Tdap; This case was reported by a nurse via call center representative and described the occurrence of allergic reaction in a female patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis.   On an unknown date, the patient received Tdap Vaccine. On an unknown date, unknown after receiving Tdap Vaccine, the patient experienced allergic reaction. On an unknown date, the outcome of the allergic reaction was unknown.   It was unknown if the reporter considered the allergic reaction to be related to Tdap Vaccine.  Additional details were provided as follows: The age at vaccination was not reported. A nurse reported that a patient experienced an allergic reaction due to the bovine content on an unspecified Tdap vaccine. The reporter consented to follow up. The nurse stated that the patient had the reaction decades ago and that she not specific report information.
DONOR STATED AFTER RECEIVING RABIES VACCINE ON 06/27/19 SHE HAD MILD SYMPTOMS DUE TO VACCINE THE DAY AFTER . SYPMTOMS INCLUDED NAUSEA W/ VOMITIMG NAD DIZZINESS. DONOR DIDNOT SEEK MEDICAL ATTENTION , STATED SHE RECOVERED NATURALLY. DONOR ONLY ADVISED STAFF OF EVENT TODAY WHILE TALKING TO STAFF.
This spontaneous report was received from a company representative. The field representative state that the doctor indicated all three female patients were administered PNEUMOVAX23 at an unknown date all three patients developed swollen lymph nodes, flu symptoms and injection site reactions. All fields apply to all three patients. No other co-suspects were reported. No concomitant medications were reported. The outcome of swollen lump nodes, injection site reactions and flu symptoms is unknown. The relatedness for swollen lump nodes, injection site reactions and flu symptoms is unknown for PNEUMOVAX23. No further information is available.
Injection site urticaria; burning sensation; injection site urticaria; injection site reaction Initial and follow-up information has been received from a 61 year old female patient, with no known pertinent medial history or drug reactions/allergies reported who on 19-OCT-2005 was vaccinated intramuscularly with a dose of pneumococcal 23v polysaccharide vaccine (lot # unknown). Concomitant therapy included loratadine (Claritin) and diphenhydramine HCL (Benadryl). On approximately 21-OCT-2005 the patient experienced a reaction at the site of injection. The patient indicated that "it felt like it was burning and had bumps." On 02-DEC-2005 the patient reported that on 01-DEC-2005 she developed 9 new bumps on her arm near the site of injection. The patient's present status was reported as recovering. No product quality complaint was involved. No additional information is expected.
Patient come to clinic for Anthrax #1 and MGC.  Patient was administered Anthrax #1 in the right deltoid and MGC in the left deltoid.  Patient tolerated both immunizations well, but when he sat down he became flush in the face and expressed nausea. Patient was immediately wheelchaired to a patient bed and was administed some water to drink with his legs elevated.  Evolution lasted approx. 12 minutes total.
This spontaneous report as received from a nurse refers to an adult patient of unknown age. The patient's concurrent conditions, medical history, concomitant medications, drug reactions or allergies were not reported. On 21-AUG-2017, the patient was vaccinated with the first dose of RECOMBIVAX HB pediatric formulation, intramuscular injection, lot # L044707, expiration date 06-OCT-2018 (also reported as 21-AUG-2017) for prophylaxis. On 02-OCT-2017, the patient was vaccinated with the second dose of RECOMBIVAX HB pediatric formulation, intramuscular injection, lot # L044707, expiration date 06-OCT-2018 (also reported as 21-AUG-2017) for prophylaxis. No adverse effects were reported.
Injection site reaction noticed at 8:00pm the day after injection. Redness, swelling, warm to touch, very tender. Approx 4" wide, 1/2" high. Ibuprofen taken and ice pack applied.